1.Composite B-cell and T-cell lymphomas: clinical, pathological, and molecular features of three cases and literature review.
Xueli JIN ; Hui LIU ; Jing LI ; Xibin XIAO ; Xianggui YUAN ; Panpan CHEN ; Boxiao CHEN ; Yun LIANG ; Fengbo HUANG
Journal of Zhejiang University. Science. B 2023;24(8):711-722
Composite lymphoma (CL) involving B-cell lymphoma and T-cell lymphoma is extremely rare. Herein, we report three such cases using immunohistochemistry, flow cytometry, and the next-generation sequencing (NGS) to identify the pathological and molecular characteristics of CL. In the first case, the patient was admitted to hospital for generalized pruritic maculopapular rash over the whole body. An excisional biopsy of the skin lesions showed T-cell lymphoma. At the same time, the staging bone marrow (BM) biopsy revealed a diffuse large B-cell lymphoma (DLBCL). After R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapies, the patient produced a good response with substantial dissipation of the rashes and relief of skin. The other two patients were admitted to hospital due to lymphadenopathy and were diagnosed with DLBCL and follicular lymphoma (FL) after core needle biopsy of lymph nodes, BM biopsy, BM aspiration, and flow cytometry. Following R-CHOP and R-COP (rituximab, cyclophosphamide, vincristine, and prednisone) therapies, they achieved complete remission unconfirmed (CRu) and complete remission (CR). However, one or two years later, they suffered a relapse of lymphadenopathy. The shocking fact was that re-biopsy of lymphadenopathy revealed peripheral T-cell lymphoma (PTCL) and angioimmunoblastic T-cell lymphoma (AITL). NGS findings identified DNA methyltransferase 3a (DNMT3a), isocitrate dehydrogenase 2 (IDH2), Ras homolog gene family, member A (RHOA), splicing factor 3B subunit 1 (SF3B1), and tumor protein p53 (TP53) mutations. After immunochemotherapy, these patients achieved CRu and CR again. Nevertheless, they suffered a second relapse of T-cell lymphoma. Finally, they died due to progression of disease. We found that the occurrence of CL is associated with Epstein-Barr virus infection and DNMT3a, IDH2, and TP53 mutations, and the prognosis of the disease is closely related to the T-cell lymphoma components.
Humans
;
Rituximab/therapeutic use*
;
Vincristine/therapeutic use*
;
Prednisone/therapeutic use*
;
Epstein-Barr Virus Infections/drug therapy*
;
Herpesvirus 4, Human
;
Neoplasm Recurrence, Local
;
Lymphoma, T-Cell/drug therapy*
;
Cyclophosphamide/therapeutic use*
;
Lymphoma, Large B-Cell, Diffuse/pathology*
;
Doxorubicin/therapeutic use*
;
Lymphadenopathy/drug therapy*
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*
2.Analysis of the genomic landscape of primary central nervous system lymphoma using whole-genome sequencing in Chinese patients.
Xianggui YUAN ; Teng YU ; Jianzhi ZHAO ; Huawei JIANG ; Yuanyuan HAO ; Wen LEI ; Yun LIANG ; Baizhou LI ; Wenbin QIAN
Frontiers of Medicine 2023;17(5):889-906
Primary central nervous system lymphoma (PCNSL) is an uncommon non-Hodgkin's lymphoma with poor prognosis. This study aimed to depict the genetic landscape of Chinese PCNSLs. Whole-genome sequencing was performed on 68 newly diagnosed Chinese PCNSL samples, whose genomic characteristics and clinicopathologic features were also analyzed. Structural variations were identified in all patients with a mean of 349, which did not significantly influence prognosis. Copy loss occurred in all samples, while gains were detected in 77.9% of the samples. The high level of copy number variations was significantly associated with poor progression-free survival (PFS) and overall survival (OS). A total of 263 genes mutated in coding regions were identified, including 6 newly discovered genes (ROBO2, KMT2C, CXCR4, MYOM2, BCLAF1, and NRXN3) detected in ⩾ 10% of the cases. CD79B mutation was significantly associated with lower PFS, TMSB4X mutation and high expression of TMSB4X protein was associated with lower OS. A prognostic risk scoring system was also established for PCNSL, which included Karnofsky performance status and six mutated genes (BRD4, EBF1, BTG1, CCND3, STAG2, and TMSB4X). Collectively, this study comprehensively reveals the genomic landscape of newly diagnosed Chinese PCNSLs, thereby enriching the present understanding of the genetic mechanisms of PCNSL.
Humans
;
DNA Copy Number Variations
;
Nuclear Proteins/genetics*
;
Central Nervous System Neoplasms/pathology*
;
Transcription Factors/genetics*
;
Prognosis
;
Lymphoma/genetics*
;
Genomics
;
China
;
Central Nervous System/pathology*
;
Bromodomain Containing Proteins
;
Cell Cycle Proteins/genetics*